The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response

Young-Min Han¹, Jong-Min Park¹, Yong Soo Choi², Hee Jin³, Yun-Sil Lee³, Na-Young Han⁴, Hookeun Lee⁴ and Ki Baik Hahm¹,5*

Abstract

Background: Radiation enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy.

Methods: We challenged a radiation-induced enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model.

Results: hPDSCs significantly improved the outcome of mice induced with either radiation enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR-induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation enteropathy.

Conclusions: hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation enteropathy.

Keywords: Placenta-derived mesenchymal stem cells, Radiation enteropathy, Regeneration, Biomarkers

* Correspondence: hahmkb@cha.ac.kr
1CHA Cancer Prevention Research Center, CHA University, CHA Bio Complex, 335 Pangyo-ro, Bundang-ku, Seongnam, Kyunggi-do 463-712, South Korea
2Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Diagnostic and therapeutic applications of irradiation (IR) are very important and useful in modern medicine [1–4]. However, IR can induce DNA damage, chromosomal aberrations, cell cycle arrest or cell death and ultimately lead to the development of malignancies [5, 6]. Though radiation therapy is commonly administered to the abdomen and pelvis of patients with gastrointestinal (GI), urological, and gynecological cancers, the toxicity of radiation to normal intestine remains the biggest obstacle. Within the gut, intestinal stem cells (SCs) and endothelial cells are especially radiosensitive, and it is common for them to be lost following IR. The loss of these cells can result in a disrupted mucosal barrier and insufficient blood supply to the gut [7, 8], and lead to troublesome radiation enteropathy. Once radiation enteropathy develops, patients may suffer from vomiting, diarrhea, abdominal pain, and bleeding [7], but unfortunately no preventive or restorative treatment modalities are available.

Since current management of radiation enteropathy is mainly supportive or surgical in those few patients that experience sustained GI bleeding [9] and there is no specific approach to prevent it, we conducted this study under the hypothesis that supplementing human placenta-derived mesenchymal stem cells (hPDSCs) can limit IR-induced enteropathy and identifying potential biomarkers to predict favorable responses to these hPDSCs can benefit clinical trials. Supported with diverse promising cell therapies including the engraftment of hematopoietic stem cells in hematological malignancies [10], the improvement of bone growth by matrix synthesis in osteogenesis imperfecta [11], the reduction of GI disorders in patients with severe resistant graft-versus-host disease (GVHD) [12], the reversion of colon peritonitis in patients with GVHD [13], and the treatment of rectovaginal and perianal fistulas in patients with Crohn’s disease [14], in the current study, we performed this proof-of-concept study to evaluate whether hPDSC administration efficiently prevents or treats radiation enteropathy through acknowledged mechanisms of restorative, anti-oxidative, anti-inflammatory, and anti-apoptotic actions of stem cells. As results, in addition to significant therapeutic effects, interleukin-10 (IL-10), Tissue inhibitor of metalloproteinases (TIMP-1), glutathione-S-transferase mu (GST mu), NADPH-oxidase4 (NOX-4), and peroxiredoxin-2 (PRDX-2) were drawn as biomarkers predicting favorable response to hPDSCs.

Methods
Cell culture
hPDSCs were provided from CHA Biotech (Seongnam, Korea). The hPDSC line was cultured in α-MEM medium containing 1 μg/ml heparin, 25 mg/ml fibroblast growth factor 4, 10% (v/v) fetal bovine serum and 100 U/ml penicillin. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂.

Animals and study protocol
C57BL/6 J mice were purchase from Central Lab. Animal Inc. (Seoul, Korea). Six-week-old female C57BL/6 J mice were fed sterilized commercial pellet diets (Biogenomics, Seoul, South Korea) and sterile water ad libitum, and housed in an air-conditioned biohazard room at a temperature of 24 °C. Group 2 and group 3 mice were subjected to a lethal dose of irradiation. Mice received total body irradiation at a dose of 7 Gy using Gammacell 300 (Best Theratronics, Kanata, ON, Canada). This study was performed under the guidelines for use and care of laboratory animals and approved by the Institutional Animal Care and Use Committee (IACUC) of the Ewha Womans University (approval number: IACUC 2013-01-048). Animal survival was monitored every 12 hours. One group of ten mice (group 1 and 2) was given intravenous injections of PBS (iNtRON Biotechnology, Seoul, South Korea) three times for 10 days. Group 3 was given intravenous injections of hPDSCs (1.0 × 10⁶/200 μl) three times for 10 days (Fig. 1a). At 10 days after irradiation, following euthanasia, the small intestines were collected, opened longitudinally, washed with sterile PBS, and tissues were analyzed following various methods. Another set of animals was prepared to document the efficacy of hPDSCs against 7 Gy radiation-induced small intestinal damage (Fig. 4a). There were five animal groups (n = 8/group); group I as the normal control, group II as the radiation-induced damage group, group III receiving hPDSCs three times before before 7 Gy irradiation, group IV receiving hPDSCs three times after 7 Gy irradiation, and group V receiving hPDSCs three times before irradiation and three times after irradiation. Animal survival was monitored every 12 hours. At 10 days after irradiation, following euthanasia, the small intestines were collected, opened longitudinally, washed with sterile PBS, and tissues were analyzed following various methods.

Antibodies
Primary antibodies for Western blotting and immunohistochemistry were purchased as follows: β-actin, Lamin B, cyclooxygenase (COX-2), nitric oxide synthase (iNOS), p53, cytochrome c, Survivin, epidermal growth factor receptor (EGFR), Ki-67 and cluster of differentiation 31 (CD31) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), phosphorylated signal transducer and activator of transcription 3 (STAT3), γ-H2AX, Bax, B-cell lymphoma 2 (Bcl-2), cleaved caspase-3, cleaved caspase-8, poly (ADP-ribose) polymerase (PARP), lysozyme and Musashi-1 from Cell Signaling Technology, Inc.(Danvers, MA, USA).
Fig. 1 (See legend on next page.)
Reverse transcriptase PCR (RT-PCR), real-time PCR and Western blots

This assay was carried out as previously described ([15, 16]). The sequences of primers are listed in Additional file 1: Table S1.

Immunohistochemical staining

After paraffin blocks were dewaxed and rehydrated with graded alcohol, tissue sections were heated in pressure jars filled with 10 mM/L citrate buffer in a microwave for 10 minutes. Slides were cooled in water for 15 - minutes and washed in PBS. The slides were incubated overnight with the primary antibody. After incubation, a subsequent reaction was formed using a Vector kit (Vector Laboratories, Inc., Burlingame, CA, USA). Finally, the slides were incubated with 3, 3′-diaminobenzidine (Invitrogen Life Technologies, Carlsbad, CA, USA) and counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO, USA).

Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining

Apoptosis was visualized using a terminal deoxynucleotidyl transferase (TdT) IRAGel DNA fragmentation detection kit (Oncogene Research Products, La Jolla, CA, USA). To determine the apoptotic index in each group, TUNEL-immunostained sections were scanned under low-power magnification (×100) to locate the apoptotic hotspots.

Measurement of luciferase activity in vivo using Xenogen luminometer

Cultured hPDSCs were seeded at a concentration achieving 80% confluence in six-well plates for 24 hours prior to transfection. The cells were transiently transfected with 0.2 μg/well of a translucent luciferase vector. After transfection, collected cells suspended in PBS were injected into mice through intravenous injection. After 1 day we injected luciferrin as substrate for luciferase vector into mice and 5 minutes later measured the luciferase activity using an Xenogen luminometer (Perkin Elmer, Waltham, MA, USA).

Proteomics analysis

Biomarker protein expression of tissues according to animal experimental group were determined using label-free quantification to compare the protein profiles in three individuals with normal intestinal tissue, irradiated tissue, and injected hPDSCs in irradiated tissue. A computational framework and tools for discovery-based liquid chromatography tandem-mass spectrometry proteomics was applied to draw the biomarkers.

Statistical analysis

All the experiments in this study were repeated more than thrice and the results are expressed as the mean ± standard deviation. The data were analyzed by one-way analysis of variance, and the statistical significance between groups was determined by Duncan’s multiple range test. Statistical significance was accepted at P < 0.05.

Results

Significant therapeutic effects of hPDSCs on radiation enteropathy

Six-week-old female mice, of C57BL/6 background, were exposed to 7 Gy IR to provoke damage to the small intestine (group 2 and group 3), among which hPDSCs (1 × 10^6/200 μl) were administered via tail vein at day 1, 4, and 7 after IR and they were sacrificed 10 days after IR (group 3) (Fig. 1a). As noted in Fig. 1b and c, small intestines were susceptible to 7 Gy IR, yielding either significantly increased wet weights of whole small intestine (P < 0.01, Fig. 1b) or significantly increased pathological scores (P < 0.0005, Fig. 1c). In detail, significant loss of small intestinal villi, intense enteritis, marked mucosal ulcerations, and even intestinal perforations were noted in jejunum or ileum after IR in group 2. However, when mice were treated with hPDSCs, 1, 4, and 7 days after IR, there were either significant decreases in wet weights of small intestine (P < 0.001) or decreases in pathological scores assessed in jejunum or ileum, separately (P < 0.005, Fig. 1c). Blood counts were taken and IR led to significant leukopenia and anemia.
(P < 0.0005, data not shown), feasibly due to bone marrow suppression, and intestinal bleeding. On gross examination of liver surface color by group, a very pale color was noted in group 2 compared with group 3 (Fig. 1b, arrows), signifying that hPDSC administration maintained normal liver surface color in addition to the unchanged wet weights of small intestine compared to the control IR group (P < 0.001). Based on pathological score system (Additional file 1: Table S2), loss of intestinal villi accompanied with inflammatory cell infiltrates was noted in jejunum and ileum of group 2 (P < 0.005), whereas the intestinal villi structure and mild degree of enteritis in jejunum and ileum were maintained in group 3 despite IR treatment (P < 0.005) (Fig. 1c). These significant differences in either gross or pathological scores between group 2 and group 3 lead us to investigate whether injected hPDSCs migrated to site of damage to exert these significant rescuing effects against IR damage and, if so, the length of time these infused cells survived within the intestine. In order to track administered stem cells, hPDSCs were transfected with luc-DNA vector and collected after 24 hours. After incubation for approximately 5–10 minutes to allow for circulation throughout the body, localization was then documented following injection of luciferin (luciferase substrate). Mice were then sacrificed and the lungs, small intestine, and colon were collected, placed on a plate, and moved to Xenogen as the bioluminescence imaging system to measure luciferase activity in each organ tested (n = 5). As seen in Fig. 1d, 1 day after hPDSC administration, luciferase expression was highly noted in the lung, small intestine, and colon (Fig. 1d). Three days later, luciferase activities were only observed in the small intestine and colon and all luciferase activity disappeared after 3 days. Next, Luc-DNA vector-transfected hPDSCs were administered to IR-treated mice (n = 5) to compare the non-irradiated and irradiated condition. There was a difference in luciferase activities according to irradiation condition, that is, a significantly increased presence of hPDSCs was noted in the small intestine of IR-treated mice compared to that of control mice (Fig. 1e), suggesting that hPDSCs homed in significantly on the intestine following IR administration and stayed for up to 3 days. Since hPDSCs originate from humans, we were able to validate the in situ existence of hPDSCs in the small intestine by performing confocal observation of tissue stained with human nucleic acids using immunohistochemistry. As seen in Fig. 1f, human nucleic acids (red spots) were present along with mouse nucleic acids (blue spots), and located in radiation-damaged villi and the nascent inflamed area of lamina propria (Fig. 1f).

Anti-inflammatory actions of hPDSCs explain the rescuing action against radiation enteropathy

We measured the changes of iNOS, COX-2, interferon gamma (IFN-γ), and interleukin (IL)-6 and compared their expression among the groups. As seen in Fig. 2a, the mRNA expressions of iNos, COX-2, IFN-γ, and IL-6 were significantly increased following IR, whereas their expressions were significantly decreased in group 3 administered with hPDSCs (P < 0.05, Fig. 2a). The decrease of IL-6, IFN-γ, and tumor necrosis factor alpha (TNF-α) mRNA levels following hPDSC administration was then confirmed by real time-PCR (P < 0.05, Fig. 2b). Western blots for iNOS, COX-2, and phosphorylated STAT3 were also conducted and compared across groups (Fig. 2c). As results, expression levels of COX-2 and iNOS were significantly increased in group 2, but significantly decreased in group 3 (P < 0.05). Phosphorylated STAT3 was also significantly increased in group 2, but significantly decreased following hPDSC administration (P < 0.05). Changes in redox-sensitive transcription factor and nuclear factor kappa B (NF-κB) expressions were significantly increased in group 2 (P < 0.01, Fig. 2d) accompanied with significantly increased levels of phosphorylated inhibitor of kappa B (IkBα) in cytoplasmic extracts from group 2 (P < 0.01). These findings were further validated with significantly increased expressions of NF-κB p50 and p65 in nuclear fractions. However, these activations of NF-κB were significantly decreased in group 3 (P < 0.01, Fig. 2d).

Restorative actions of hPDSCs led to significant therapeutic outcome against radiation enteropathy

Since proliferative and regenerative actions are basic features of stem cells, we selected five targets explaining the significant rescuing action of hPDSCs against radiation enteropathy, CD31 (angiogenic activity [17]), EGFR and Ki-67 (regenerating action [18]), and lysozyme and Musashi-1 (Paneth cell and stemness [18, 19]). As shown in Fig. 3a, significant decrease in CD31 and EGFR expression with radiation damage were significantly restored following the administration of hPDSCs (P < 0.05). The heights of Ki67-positive crypts were significantly decreased in group 2 (P < 0.01), but their levels were significantly preserved in spite of IR, suggesting that hPDSC infusion faithfully contributed to the regeneration of the ulcerated tissue structure, reflected with Ki67-positive cells. When we performed immunostaining for stem cell markers including lysozyme and Musashi-1, all of these stemness markers were all significantly decreased in group 2 (P < 0.05), but restored in group 3 following the administration of hPDSCs (P < 0.01). In detail, the levels of lysozyme antibodies denoting Paneth cells, implicated in either defending epithelial maintenance or cell renewal [20],
were significantly decreased in group 2 ($P < 0.01$), whereas their expression was significantly increased in group 3 ($P < 0.01$). Musashi-1 expression was also significantly decreased in group 2 ($P < 0.005$), but its expression was significantly increased in group 3 ($P < 0.01$, Fig. 3a). IR treatment results in oxidative stress and induced apoptosis in affected organs. Western blotting was done to compare the expression of apoptotic molecules including cleaved caspase-8 or caspase-3, PARP, cytochrome c release, p53, and γ-H2AX. As seen in Fig. 3b, group 2 showed increased expressions of these apoptotic executors or prone gene expression except Bcl-2, but these results were mitigated by the administration of hPDSCs. These molecular changes were further validated with TUNEL and immunohistochemical staining for p53 and survivin (Fig. 3c). Ten days after irradiation, we observed a six- and fivefold increase in apoptotic epithelial cells in the small intestine using TUNEL assay and p53 staining, respectively ($P < 0.01$, Fig. 3c). However, hPDSC infusion into the irradiated mice group decreased the percentage of apoptotic cells ($P < 0.005$). The number of survivin (as anti-apoptotic factor)-positive cells in the crypt compartment returned to values close to the normal control in the hPDSC-treated group ($P < 0.005$), while survivin-positive cells were significantly diminished in the irradiated group ($P < 0.005$, Fig. 3c). Changes in tight junction were also principally implicated in IR intestinal damage. As shown in Fig. 3d, the expressions of occludin-1 or ZO-1 were both significantly decreased in group 2 ($P < 0.01$), but these expressions were significantly maintained in group 3 ($P < 0.01$). Lastly, when matrix metalloproteinase-2 (MMP-2) protease activities were measured by zymography, significantly increased activities of MMP-2 were shown in
Fig. 3 (See legend on next page.)
group 2 ($P < 0.01$), but significantly decreased in group 3 ($P < 0.005$, Fig. 3e).

**Prophylactic effects of hPDSCs against either radiation enteropathy or lethal radiation syndrome**

In order to know whether hPDSCs could prevent IR-induced intestinal damage, further studies were conducted using additional groups, group III as pre-administration, group IV as co-administration, and group V as both pre- and post-administration (Fig. 4a). As results, groups III, IV, and V all showed significant rescuing outcomes from radiation-induced intestinal damage (Fig. 4b and c). Regarding the changes of wet weights of small intestine, as seen in Fig. 4b, all hPDSC-treated groups, irrespective of administration timing, showed significant protection against 7 Gy IR ($P < 0.005$). These beneficial effects of hPDSCs were also verified to be statistically significant on pathological scoring ($P < 0.005$, Fig. 4c), even though results indicated a distinction of effective extent between each group. Western blots of iNOS and COX-2 consistently showed significantly attenuating effects irrespective of the administration timing of hPDSCs (Fig. 4d). Since IR causes intestinal damage through oxidative stress, serum concentration of lipid peroxidation, as measured by MDA levels, was most highly elevated in group II compared to group I ($P < 0.001$, Fig. 4e). On the other hand, group IV and V showed significantly decreased levels of serum MDA compared to group II ($P < 0.01$, Fig. 4e). Beside the intestinal protection observed following the administration of hPDSCs, we investigated whether hPDSCs can rescue mice from system radiation syndrome. For these analyses, mice ($n = 10$) were exposed to 10 Gy and mortality was tracked with irradiation alone and a group receiving $1.0 \times 10^6$ hPDSCs via tail vein. One and 4 days after 10 Gy IR, as seen in Fig. 4f, IR led to about 50% mortality within 7 days and almost 100% lethality after 9 days. However hPDSCs administration after 10 Gy IR maintained 100% survival up to 9 days and 70% survival up to 15 days ($P < 0.001$, Fig 4f). Upon necropsy, 10 Gy IR provoked serious radiation syndrome manifested with bone marrow failure as evidenced by acellular marrow, extensive hepatic necrosis, respiratory failure due to extensive pneumonitis, and splenic hypoplasia (Fig. 4g). On the other hand, following administration of hPDSCs, all of these lethal changes imposed by the 10 Gy IR were significantly recovered in bone marrow, liver, lung, and spleen, respectively (Fig. 4g). Conclusively, hPDSC afforded significant protection from either radiation-induced small intestinal damage or lethal radiation syndrome.

**Label-free quantification analysis to discover significant proteomic biomarkers implicated in rescuing action of hPDSCs against radiation enteropathy**

In order to discriminate proteomic changes implicated in either IR-induced intestinal damage or rescuing through hPDSC administration, we performed comparative proteomic analysis using label-free quantification analysis with quadrupole time-of-flight (Q-TOF) mass spectrometry. As results, as seen in Fig. 5a, we pulled out whole proteomes from group 1 ($n = 186$), group 2 ($n = 270$), and group 3 ($n = 238$) and conducted a comparative gene ontology (GO) analysis. These 143 spots, including three groups in common were changed according to group condition (see Additional file 1: Table S3). Upon the serial comparative analysis, we categorized these proteome spots into five groups (Fig. 5b). Briefly, we could confirm that hPDSCs imposed antioxidative, cell differentiation, and tissue repair, whereas they resulted in the inhibition of signal transduction relevant to inflammation, oxidative stress, and ion transport and the changing patterns could be categorized into five patterns as seen in Fig. 5b, among which the following three pattern types were prominent, that is, proteome spots significantly decreased in group 2, whereas significantly increased in group 3 (Fig. 5c and Table 1), proteomic spots significantly increased in group 2, but significantly decreased in group 3 (Fig. 5d and Table 1), and proteomic spots were not changed in group 2, but significantly increased in group 3 (Fig. 5e and Table 1). The proteomic spots identified as proteomic biomarkers signifying “elevated following IR, but decreased following administration of hPDSCs” were phosphatidylethanolamine-binding protein 1 (PEBP1),...
Fig. 4 (See legend on next page.)
apoptosis-associated speck-like protein containing CARD (PYCARD), glycerol 3-phosphate dehydrogenase [NAD (+)], cytoplasmic (GPD1) and ornithine carbamoyltransferase, mitochondria (OTC) (Fig. 5d and Table 1), and three proteomic spots, identified as proteomic biomarkers containing “no significant changes following IR, but increased following administration of hPDSCs” were tubulin-α-1B chain (TUBA1B), cytochrome c oxidase subunit 2 (MT-CO2), and peroxiredoxin-2 (PRDX-2) (Fig 5e and Table 1). To draw significant proteomic biomarkers with validation, proteomic biomarkers signifying “downregulated following IR, but increased following administration of hPDSCs”, IL-10, TIMP-1, and GST mu type 1 (GST mu1) were done with Western blot using homogenates from each group (Fig. 6a and b). As validation to these discoveries, as shown in Fig. 6a, the expression levels of IL-10 were decreased with irradiation (P < 0.001), but these levels were increased in group 3 (P < 0.05). When cells were irradiated, their destruction is enhanced through the activation of MMPs, especially MMP-2 or MMP-9, an enzyme pathway initiated by p53 [21]. TIMP-1 is a glycoprotein expressed from several tissues [22] as a natural inhibitor of MMPs [23], and has also been reported to reflect protection against IR-induced tissue damage. As shown in Fig. 6a, TIMP-1 was decreased in group 2 (P < 0.05), but its level increased following hPDSC administration (P < 0.0005). As already seen in Fig. 3c,
MMP-2 activity was significantly increased in group 2. GST μ type—known as a strong anti-oxidant marker—was upregulated in group 3 whereas a decrease in expression of this protein was observed in group 2 (P < 0.05, Fig. 6b). Cancellation of NOX-4, OTC and GPD1 was validated as a biomarker predicting favorable response with hPDSC administration (Fig. 6c). As a biomarker unchanged as a result of IR treatment, but increased following hPDSC administration, GST (pi) and PRDX-2—known as a strongly anti-oxidative factor—was validated (P < 0.05, Fig. 6d).

**Discussion**

In contrast to previous reports that MSCs afforded the protective efficacies of MSCs against radiation enteropathy [17, 24–31], our results clearly showed that hPDSCs can be applied for either prophylactic or therapeutic purposes against radiation enteropathy. Also, we successfully elucidated potential biomarkers predicting a favorable response to stem cell therapy. Detailed summarization showed that hPDSCs, (i) significantly rescued mice from radiation syndrome by relieving systemic inflammatory response syndrome, (ii) significantly reduced the inflammation and apoptosis of cells within the small intestine subsequent to IR-induced robust oxidative stress, (iii) significantly afforded the recovery of the small intestine via either ameliorated apoptosis or enhanced anti-apoptosis, (iv) significantly resisted the loss of IR-induced stem cells essential for regeneration.

**Table 1** Label-free quantification analysis: novel biomarker candidates

| Protein description                                      | G1       | G2       | G3       |
|----------------------------------------------------------|----------|----------|----------|
| Fatty acid-binding protein, adipocyte                    | 1        | 1.6125   | 0.7874   |
| Heat shock protein 75 kDa, mitochondrial                 | 1        | 1.7864   | 0.9751   |
| RIKEN cDNA 2210010C04, isoform CRA_b                      | 1        | 2.9038   | 1.1034   |
| Neurobeachin-like protein 2                               | 1        | 7.2087   | 3.2829   |
| Gelsolin                                                 | 1        | 9.6935   | 3.3595   |
| Nucleolin                                                | 1        | 11.1004  | 5.0287   |
| Phosphatidylethanolamine-binding protein 1                | 1        | 12.4758  | 1.8796   |
| Protein 6530409C15Rik                                     | 1        | 15.1723  | 9.6556   |
| Apoptosis-associated speck-like protein containing a CARD | 1        | 24.5311  | 0.9818   |
| Nucleoside diphosphate kinase B                           | 1        | 25.2488  | 15.8437  |
| Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic | 1        | 38.2966  | 21.2440  |
| Tropomyosin alpha-3 chain                                 | 1        | 40.7211  | 0.30890  |
| 60S ribosomal protein L22                                 | 1        | 598.3902 | 127.068  |
| Ornithine carbamoyltransferase, mitochondrial             | 1        | 249659   | 163892   |
| Histone H4                                                | 1        | 609717   | 304923   |
| Proteomes increased after irradiation (G2) compared to control (G1), but decreased with hPDSC (G3) |
| Protein Mpx 2                                             | 1        | 0.1956   | 0.5902   |
| Glutathione S-transferase Mu 1                            | 1        | 0.2547   | 7.3523   |
| Proteomes not changed with irradiation (G2) compared to control (G1), but increased with hPDSC (G3) |
| Profilin-1                                                | 1        | 0.7039   | 3.2086   |
| Myosin-10                                                 | 1        | 0.8149   | 11.362   |
| Tubulin alpha-1B chain                                    | 1        | 0.8376   | 17.0778  |
| Macolin                                                  | 1        | 0.8532   | 6.89827  |
| Cytochrome c oxidase subunit 2                            | 1        | 0.9668   | 2.58191  |
| Gastrotropin                                              | 1        | 1.09828  | 1.81219  |
| Peptidyl-prolyl cis-trans isomerase A                     | 1        | 1.3439   | 21.883   |
| Malatase-glucosaminylase                                  | 1        | 1.3488   | 6.0850   |
| Peroxiredoxin-2                                           | 1        | 1.3426   | 4.2072   |
| Histone H2A type 1-F                                      | 1        | 1.4423   | 4.6122   |
| Calnexin                                                  | 1        | 1.4684   | 2.8897   |
and (v) cell therapy can be tailored through discovery of biomarkers predicting of favorable responses with hPDSCs. Similar to previous publications seeking solutions for radiation-induced intestinal toxicity through cell therapy, hPDSCs in the current study effectively enhanced or maintained the re-epithelization process along with significantly concerted actions of anti-inflammation, anti-oxidation, and anti-apoptosis. Though beneficial effects have been reported with small molecules acting as either a prolyl hydroxylase inhibitor or a Rho kinase inhibitor (Y-27632) [26], autophagy induction [31], natural products like hyaluronic acid, drugs like sucralfate [28], polaprezinc, coniferyl aldehyde as heat shock factor-1-inducing agent [29], amifostine [32], and tocotrienol as heat shock factor-1-inducing agent [29], amifostine [32], and tocotrienol [33], oral budesonide, lactobacillus probiotics [30] against radiation intestinal damage, substantial differences exist with our current study, that is, supplementing the loss of stem cells and concerted mechanisms for regeneration via stem cells might be fundamental and essential in radiation enteritis. Considering the unmet medical needs that current management of radiation-induced intestinal damage is only supportive and supplementary [9], intestinal SCs and bone marrow are very vulnerable to IR, and Lgr5 + stem cells are indispensable for radiation-induced intestinal regeneration [18], MSCs can play an important role in repairing tissue injury based on their self-renewal and multi-differentiation potential. Conclusively, current documentation of radiobiological effects of hPDSCs remains a challenge when seeking a safe strategy to either prevent or treat troublesome radiation enteropathy.

Furthermore, hPDSCs afforded significant protection from fatal acute radiation syndrome (Fig. 4f and g) beyond significant rescuing efficacy from IR-induced intestinal damage. Hence, hPDSCs protected irradiated mice by either inducing hematopoiesis or reducing apoptosis in affected organs. In this protection, three major mechanisms of MSC-induced hematopoiesis contributed,
one is comparatively scarce cytokine-like granulocyte-macrophage colony-stimulating factor (GM-CSF), stromal cell-derived factor-1 (SDF-1), and IL-6 after irradiation, but make up for cytokine shortage by MSCs [34], the second is the recovery of the hematopoietic microenvironment destroyed by irradiation [35], and lastly, the regeneration of radiation-damaged bone marrow (BM) niche along with the protection of hematopoietic cells from apoptosis [25]. The classic understanding of radiation enteropathy was based on “the single target cell” concept around the 1920s and 1930s, but nowadays, extended to intestinal microvasculature, immune mechanisms, neuroimmune interactions, gut microbiome, the composition of the intraluminal contents, and other host factors [36]. Radiation predominantly kills rapidly proliferating cells such as progenitor cells in the intestinal crypts, leading to insufficient replacement of the villus epithelium [37] as seen in Fig. 2a, and induces many changes in endothelial cells including apoptosis, detached basement membrane, increased permeability, and interstitial fibrin deposition [38]. In this situation, SCs migrated to irradiation-exposed sites [39], produced vital growth factors and anti-oxidants in a paracrine manner [40], transdifferentiated to form damaged intestinal functional cells [41], and endowed authentic proliferative activities, which can open up the hope of exciting new cell therapeutic strategies as seen in Fig. 1d-f.

Various types of MSCs have been reported to be effective against radiation enteropathy including human adipose-derived MSCs [17], BM-derived MSCs (BMSCs) [42, 43], mesenchymal stromal cells [27, 44], placental stromal cells [25]. Horton et al. [45] showed that BMSCs could alter the progression of radiation-induced fibrosis by altering macrophage phenotype and suppressing local inflammation. As described by Auletta et al. [46], stem cells afforded the multi-potent and multi-therapeutic effects for host defense and MSCs homed significantly to irradiation-exposed sites, but also promotes their widespread engraftment to multiple organs, strongly supporting the use of MSCs to repair damaged normal tissues either following accidental irradiation or radiotherapy [39]. Though the signaling pathway responsible for these homing effects still remains unknown, it is inferred that molecular mediators such as chemokines and cytokines might orchestrate this process [47].

Though translational studies will be required to define the future clinical applications, from our study, we recommend thrice administration of intravenous 1 × 10^6 hPDSCs every week. Though we have tried other kinds of MSCs, adipose-derived MSC, umbilical cord-derived MSG, and BM-derived MSC under the same experimental models, the conclusion was that current hPDSCs showed the best efficacy among these MSCs and showed the lowest immunogenicity compared to other kinds of allogenic MSCs (data not shown). Stem cell niche include both WNT and BMP signaling pathway, and the balance between their signaling is important within the intestine [48]. The WNT signaling pathway has emerged as a potential regulator of self-renewal for intestinal stem cells [49]. In the current study, we identified markers of the stem cell niche including Noggin, DLL4 and WNTs. As a result, the expression of Noggin was found to be remarkably increased in the hPDSC-treated group as compared to both the irradiated and control group and WNT6 slightly increased in the hPDSC-treated group (data was not shown).

Another important tip for future clinical application of hPDSCs came from our effort to discover biomarkers to predict the favorable response after hPDSC administration (Figs. 5 and 6), of which a validation study showed an increase in mucosal expression of IL-10, OTC1, mitochondrial sn-glycerol 3-phosphate dehydrogenase (mGPDH), TIMP-1, GSTM1, NOX4, and PRDX2 can be biomarkers significantly suggestive of favorable responses to hPDSCs. Looking at the biological action of discovered biomarkers, core mechanisms of hPDSCs against radiation enteropathy included efficient anti-inflammation and antioxidation and regeneration. Inferring more, IL-10, beyond being a well-known anti-inflammatory cytokine, is considered a key regulator of licensing regulatory T cells relevant to allogenic stem cells [50] and stem cell renewal to promote their regeneration [51]; changes of OTC1 (though this gene is involved in neuropathology due to deficiency [52]), is only identified in one report relevant to roentgen irradiation [53], mGPDH1 as a ubiquinone-linked enzyme in the mitochondrial inner membrane (though the physiological role of this enzyme remains poorly defined in many tissues), might play a compensatory role in pathways for cytosolic regeneration of NAD+ and mechanisms for glycerol phosphate metabolism relevant to irradiation [54], and TIMP1, a tissue inhibitor of MMPs contributes to MSCs-induced healing [55]. In a recent publication by Haubner et al. [56], MSCs like ADSCs stimulated wound healing via increased TIMP1 and TIMPs in radiotherapy-associated impaired wound healing. GSTM1 were already reported to be genetic predictors of long-term toxicities after radiation therapy [57], NOX-4 as inducer of total body irradiation-induced hematopoietic genomic instability [58], and PRDX2 as UV responses and radiation in human skin [59].

Conclusions
Conclusively, hPDSCs, featured with relative low immunogenicity compared to other kinds of allogenic MSCs, afforded prophylactic and therapeutic actions against troublesome radiation enteropathy through well-
orchestrated actions including anti-inflammation, anti-oxidation, cytoprotection, and regeneration. Though further detailed clinical trials are required, our identification of biomarkers predicting favorable responses can add to the tailored application of SC therapeutics in alleviating radiation enteropathy.

Additional file

Additional file 1: Table S1. Primers used in the current study. Table S2. Criteria used for pathological grading in the current study. Table S3. Analysis of proteomics: proteome showing difference between G2 and G3 (P < 0.05). (DOC 185 kb)

Abbreviations

Bcl-2: B-cell lymphoma 2; BMSCs: Bone marrow-derived stem cells; CD31: Cluster of differentiation 31; COX-2: Cyclooxygenase-2; EGFR: Epidermal growth factor receptor; GI: Gastrointestinal; GO: Gene ontology; GPD1: Glycerol 3-phosphate dehydrogenase; HFPDCs: Human placenta-derived mesenchymal stem cells; IFN-γ: Interferon gamma; iCGG: Inhibitor of kappa B; IL-10: Interleukin-10; IL-6: Interleukin 6; INOS: Nitric oxide synthase; IR: Ionizing radiation; mGPDH: Mitochondrial sn-glycerol 3-phosphate dehydrogenase; MMP-2: Matrix metalloproteinase-2; MT-CO2: Cytochrome c oxidase subunit 2; NF-κB: Nuclear factor-κB; NOX-4: NADPH-oxidase 4; OTC: Ornithine carbamoyltransferase; PARP: Poly (ADP-ribose) polymerase; PEBP1: Phosphatidylethanolamine-binding protein 1; PRDX-2: Peroxiredoxin-2; PYCARD: Apoptosis-associated speck-like protein containing CARD; Q-TOF: Quadrupole time-of-flight; SCs: Stem cells; STAT3: Signal transducer and activator of transcription 3; TNF-α: Tumor necrosis factor alpha; TUBA1B: Tubulin-α-1B chain; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling

Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2058732).

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2058732).

Availability of data and materials

The authors declare that all other data supporting the findings of this study are available within the article and its supplementary information files.

Authors’ contributions

YMH and JMP performed all the experimental work. YSC provided hPDSCs and HJ and YSL contributed to the radiation damage experiment. NYH and JMP performed all the experimental work. YSC provided hPDSCs to JYH. YMH and KBH wrote the manuscript and directed all the experimental work. YMH and JMP performed all the experimental work. YSC provided hPDSCs and directed the final experimental work. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The hPDSCs were provided from CHA Biotech (Seongnam, Korea) and subsequent experiments were authorized by the Institutional Animal Care and Use Committee (IACUC) of the Ewha Womans University (Republic of Korea) under approval number IACUC 2013-01-048.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1CHA Cancer Prevention Research Center, CHA University, CHA Bio Complex, 335 Pungyo-ro, Bundang-ku, Seongnam, Kyunggi-do, 463-712, South Korea. 2Department of Applied Bioscience, CHA University, Seongnam, South Korea. 3Graduated School of Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea. 4Lee Gil Ya Cancer and Diabetes Institute, College of Pharmacy, Gachon University, Incheon, South Korea. 5Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.

Received: 24 January 2017 Revised: 22 March 2017 Accepted: 8 April 2017 Published online: 02 May 2017

References

1. Willson KD, Sun N, Huang M, Zhang WY, Lee AS, Li Z, Wang SX, Wu JC. Effects of ionizing radiation on self-renewal and pluripotency of human embryonic stem cells. Cancer Res. 2010;70:5539–48.
2. Meyer J, Czito B, Yin FF, Willett C. Advanced radiation therapy technologies in the treatment of rectal and anal cancer. Intensity-modulated proton therapy and proton therapy. Clin Colorectal Cancer. 2007;6:548–56.
3. Schulz-Ertner D. The clinical experience with particle therapy in adults. Cancer J. 2009;15:230–11.
4. Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw. 2010;8:123–9.
5. Wang Y, Liu L, Pazhanisamy SK, Li H, Meng A, Zhou D. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic Biol Med. 2010;48:548–56.
6. Cadet J, Delatour T, Douki T, Gasparutto D, Pouget JP, Ravanat JL, Sauvaigo S. Hydroxyl radicals and DNA base damage. Mutat Res. 1999;424:29–49.
7. Umar S. Intestinal stem cells. Curr Gastroenterol Rep. 2010;12:340–8.
8. Wang J, Boerma M, Fu Q, Hauer-Jensen M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol. 2007;13:3047–55.
9. Kontouras J, Zavos C. Recent advances in the management of radiation colitis. World J Gastroenterol. 2008;14:7289–301.
10. Fouillard L, Bensidhoum M, Bories D, Bories D, Bonte H, Lopez M, Moseley AM, Smith P, Le Sage S, Beauchamp F, Thierry D, et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia. 2003;17:474–6.
11. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal stem cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99:8932–7.
12. Le Blanc K, Rommanson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
13. Ringden O, Uzunel M, Sundberg B, Lonnnes I, Nava S, Gustafsson J, Henningsjo H, Le Blanc K. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumoniediastinum and perforated colon. Leukemia. 2007;21:2271–6.
14. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s disease with adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416–23.
15. Han YM, Hahm KB, Park JM, Hong SP, Kim EH. Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model. Neoplasia. 2014;16:73–83.
16. Han YM, Park JM, Cha JY, Jeong M, Go EJ, Hahm KB. Endogenous conversion of omega-6 to omega-3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/beta-catenin signaling or activating 15-PGDH/L-18. Int J Cancer. 2016;138:2247–56.
17. Chang P, Qu Y, Liu Y, Cui S, Zhu D, Wang H, Jin X. Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury. Cell Death Dis. 2013;4:e685.
18. Metzalf C, Kjavin NM, Ybarra R, de Sauvage FJ. Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell. 2014;14:149–59.

19. Mullin JM, Valenzano MC, Whitty M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mencogliano G, Thornton JJ. Esomeprazole induces upper gastrointestinal tract mucosal permeability increase. Aliment Pharmacol Ther. 2008;28:1317–25.

20. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol. 2011;9:356–68.

21. He M, Dong C, Ren R, Yuan D, Xie Y, Pan Y, Shao C. Radiation enhances the down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. Pathol Biol (Paris). 2003;51:569–73.

22. Hu XQ, Sun QY, Guo M, Ai HS. The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury. Br J Radiol. 2010;83:52–8.

23. Gaberman E, Pinzur L, Levdansky L, Tsrolin M, Netzer N, Abemar Z, Gorodesky R. Mitigation of lethal radiation syndrome in mice by intramuscular injection of 3D cultured adherent human placental stromal cells. PLoS One. 2013;8:e66549.

24. Gao Z, Zhang Q, Han Y, Cheng X, Lu Y, Fan L, Wu Z. Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice. Cytotherapy. 2012;14:267–73.

25. Matsuu-Matsuyama M, Shichijo K, Okuichi K, Ishii K, Wen CY, Fukuda E, Nakayama T, Nakashima M, Uemura T, Niino D, Sekine I. Protection by polaprezinc against radiation-induced apoptosis in rats. J Radiat Res. 2006;47:1–8.

26. Matsuu-Matsuyama M, Shichijo K, Okuichi K, Nakayama T, Nakashima M, Uemura T, Niino D, Sekine I. Protection by polaprezinc against radiation-induced apoptosis in rat jejunum crypt cells. J Radiat Res. 2008;49:341–7.

27. Ciorda MA, Riehl TE, Ruo MS, Moon C, Ee X, Nava GM, Walker MR, Mainsham JW, Stepperenck TS, Stenson WF. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61:829–38.

28. Hou J, Han ZP, Jing YY, Yang X, Zhang SS, Sun K, Hao C, Meng Y, Yu FH, Liu XQ, et al. Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis. 2013;4:e8944.

29. Ben-Josef E, Han S, Tobi M, Vargas BJ, Stamos B, Kelly L, Biggar S, Kaplan I. Down-regulation of tissue inhibitor of matrix metalloproteinases. Genome Biol. 2011;12:233.

30. Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, Walker MR, Matsuu-Matsuyama M, Shichijo K, Okaichi K, Ishii K, Wen CY, Fukuda E, Nakayama T, Nakashima M, Uemura T, Niino D, Sekine I. Protection by polaprezinc against radiation-induced apoptosis in rats. J Radiat Res. 2006;47:1–8.

31. Auletta JJ, Deans RJ, Balbolonew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood. 2012;119:1801–9.

32. Nair S, Reiberger E, Klar E, Wang J, Kumar KS, Hauer-Jensen M. Gamma irradiation induced apoptosis in rat jejunal crypt cells. J Radiat Res. 2008;49:341–7.

33. Berbee M, Fu Q, Boerma M, Wang J, Han X, Liang S, Song L, Poli E. Neuro-glial differentiation of human bone marrow stromal cells in vitro. Exp Neurol. 2005;193:312–25.

34. Semont A, Moussedine M, Franciosi A, Demarquay C, Mathieu N, Chapel A, Sache A, Thierry D, Lalo P, Gournelom P. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 2010;17:952–61.

35. Linard C, Busson E, Holler V, Strup-Perrot C, Lacave-Lapalun JV, Lhomme B, Prat M, Devauchelle P, Sabourin JC, Simon JM, et al. Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs. Stem Cells Transl Med. 2013;2:916–27.

36. Horvitz EM, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10:771–4.

37. Horton JA, Hudak KE, Chung EI, White AO, Scroggins BT, Burkeen JF, Citrin DE. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31:2321–41.

38. Giaccia AJ. PHD inhibition mitigates and protects against radiation-induced cellular injury. Blood. 2014;123:810–9.

39. Kearney K, Lazowick D, Mercogliano G, Thornton JJ. Esomeprazole induces radiation-induced proctitis in pigs. Stem Cells Transl Med. 2013;2:916–27.

40. Gnecci M, Zhang Z, Ni A, Draz VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204–19.